dpp4 vs glp 1 GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes GLP‑1 and DPP-4 inhibitors in current diabetes

Clinical trials demonstrated average weight reductions of 15-21% of body weight over 72 weeks in people with obesity (SURMOUNT-1), while more modest weight loss was observed in type 2 diabetes patients (SURPASS trials)

doi:10.7759/cureus.22849

In clinical practice, adjustments to MCP-1-targeted strategiessuch as accounting for the monocyte-to-neutrophil ratio, oxygenation index, and concurrent medicationsshould be made with careful consideration of each patients comorbidities

J., Jones, D

L-Carnitine is important for providing energy to muscles, and has been described as a conditionally essential nutrient for humans